scispace - formally typeset
D

Donna J. Ingles

Researcher at University of South Florida

Publications -  17
Citations -  529

Donna J. Ingles is an academic researcher from University of South Florida. The author has contributed to research in topics: HPV infection & Population. The author has an hindex of 11, co-authored 15 publications receiving 460 citations.

Papers
More filters
Journal ArticleDOI

A Novel Approach to the Discovery of Small-Molecule Ligands of CDK2.

TL;DR: Although this small compound library contained only ATP‐site‐directed ligands, the application of this assay to large compound libraries has the potential to reveal previously unrecognized chemical scaffolds suitable for structure‐based design of CDK2 inhibitors with new mechanisms of action.
Journal ArticleDOI

Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial.

TL;DR: This is the first study demonstrating that vaccination of males with Gardasil induces HPV antibody levels at the oral cavity that correlate with circulating levels, and these levels were significantly correlated with serum levels.
Journal ArticleDOI

Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study.

TL;DR: Most EGLs develop following infection with HPV 6, 11, or 16, all of which could be prevented with the 4-valent HPV vaccine, according to a prospective analysis nested within the HPV Infection in Men study.
Journal ArticleDOI

Long-term persistence of oral human papillomavirus type 16: the HPV Infection in Men (HIM) study

TL;DR: Prevalent oral HPV16 infections in men persisted longer than newly acquired infections, and persistence appeared to increase with age, which may explain the high prevalence of oral HPV observed at older ages.
Journal ArticleDOI

Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study.

TL;DR: The immune response to HPV vaccination in men ages 27-45 was comparable to that observed in younger men, in whom clinical efficacy was demonstrated and further trials to assess the efficacy of HPV vaccines to prevent persistent HPV infections in mid-adult men are needed.